ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs
The content of this joint guidance was developed by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) with the support of a technical advisory group composed of policy makers, service providers, civil society representatives and preventative health experts from throughout the EU/EEA.
ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs - guidance in brief
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national strategies and programmes in countries in Europe in order to reduce and prevent infections among people who inject drugs.
HIV and hepatitis B and C in Latvia
At the request of the Ministry of Health in Riga, a team of experts from ECDC and the European Monitoring Centre for Drugs and Drug Addiction paid a technical visit to Latvia on 2–4 September 2014.
Behavioural surveillance toolkitArchived
The overall objective of this work is to support the development of a key set of indicators in order to ensure availability of comparable behavioural data and to support Member States to implement behavioural surveillance or surveys by preparing a user-friendly toolkit and framework (protocol) for the implementation of behavioural surveillance and second generation surveillance related to HIV and STI in Europe.
Technical guidance on the Introduction of HPV vaccines in European Union countries – an update
In January 2008, a panel of ECDC experts produced the Guidance for the introduction of HPV vaccines in EU countries. Since then, the European Union has come a long way: most countries have implemented national vaccination programmes for adolescent girls and a significant number have also introduced catch-up programmes for young women.
Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.